June 20, 2021
Business News

Infinity Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Company Update


CAMBRIDGE, Mass.–()–Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its first quarter 2021 financial results and provided a corporate update.

“2021 is poised to be a landmark year for Infinity with meaningful data updates, building on important data presentations over the last few months, which support the potential of eganelisib’s unique immune modulatory mechanism to improve outcomes across multiple solid tumor indications, lines of therapies and treatment combinations,” said Adelene Perkins,…



Click here to view the original article.

Related Posts

You might also like ...

DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
AON Splash Image
Tablet Prime Day Deals (2021): Early Apple iPad, Samsung Galaxy Tablet, Fire HD & Kindle Savings Monitored by Retail Egg
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Arcimoto, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm